Faron Pharmaceuticals

Faron Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing innovative immunotherapy treatments for cancers with significant unmet medical needs. Based in Turku, Finland with an office in Boston, Massachusetts, Faron's lead asset is bexmarilimab, a novel anti-Clever-1 antibody that reprograms the tumor microenvironment by switching immune suppression to immune activation. Bexmarilimab targets Clever-1, a receptor on immunosuppressive macrophages and malignant blasts, and is currently being investigated in multiple clinical trials for hematological malignancies including acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), as well as solid tumors. In Phase I/II BEXMAB clinical trials, bexmarilimab has demonstrated an 85% overall response rate and 45% complete response rate in frontline higher-risk MDS patients, with median complete response duration of 16.1 months. Faron is listed on the London Stock Exchange AIM market under the ticker FARN and on Nasdaq First North Growth Market under the ticker FARON.